Krsnaa Diagnostics Limited (NSE: KRSNAA), one of India’s leading integrated diagnostic service providers, today announced its financial and operating performance for the quarter and half year ended September 30, 2026. Revenue from operations grew 32% YoY to Rs 2,710 million, marking the company’s highest ever quarterly revenue. This growth was driven by contributions from newly operationalized projects, continued growth in existing operations, and expansion of the retail business.

Retail Business Momentum

Retail revenue grew 35% YoY to Rs 235 million, with patient volumes increasing 45% and test volumes growing 48%. The segment contributed approximately 9% of overall revenue, supported by an asset-light network of franchisees, business associates, referral centers, and strategic alliances.

Project Execution and Radiology Expansion

The company continued to focus on stabilizing and improving utilisation across PPP projects, including Rajasthan. Radiology operations are supported by over 350 radiologists, with teleradiology capabilities across X-ray, CT, and MRI. The Company has 57 NABL-accredited pathology laboratories and 75 NABH-accredited radiology centres.

Commenting on the results, Mr. Yash Mutha, Managing Director, said: “Q2 FY27 reflects the continued growth of our diagnostic platform, supported by our established business and contributions from newly operationalized projects. Our focus remains on strengthening our existing PPP presence, capitalizing available opportunity in existing and untapped geographies and focus on accelerating cash business and building retail diagnostics as a complementary growth engine. We are also expanding specialized diagnostic offerings and exploring technology-led opportunities to enhance the reach and efficiency of our services.”

Mr. Mitesh Dave, Group Chief Executive Officer, said: “Our focus during the quarter remained on execution and improving utilization across our expanding network. We are seeing encouraging traction in retail, with healthy growth in patient and test volumes. Alongside this, we continue to strengthen our radiology and pathology capabilities in an integrated manner. As our newer projects mature, we remain focused on improving operational efficiency and delivering a better patient experience.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Krsnaa Diagnostics Limited

Krsnaa Diagnostics Limited belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Krsnaa trades in the lower quarter of its 52-week range. The business compounds revenue at 16.6% and profits at 17.8% CAGR. That is strong double-digit growth on both counts. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Buyers show up with 6.5x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. Revenue grows at 16.6% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Krsnaa Diagnostics Limited.

Akums Drugs & Pharmaceuticals Ltd (AKUMS) announced its consolidated financial results for the quarter ended September 30, 2026. The company reported a 31.9% year-on-year revenue growth to ₹1,342 crore, driven by its Contract Development and Manufacturing Organisation (CDMO) business. The EBITDA surged by 106% to ₹195 crore, while Profit After Tax (PAT) jumped by 168% to ₹115 crore. The company’s strong performance was supported by robust demand and improved operating performance.

Revenue and Profitability

For Q2 FY27, Akums’ revenue stood at ₹1,342 crore, compared to ₹1,018 crore in the same quarter last year. The EBITDA margin improved to 14.5% from 9.3% in Q2 FY26. The PAT margin also improved to 8.4% from 4.1%. The company’s focus on operational excellence and consistent quality has paid off, leading to significant growth in both revenue and profitability.

CDMO Business Performance

The CDMO business continued to be the key growth driver, reporting a year-on-year revenue growth of 38.6% to ₹1,115 crore. CDMO EBITDA increased by 99.6% to ₹168 crore, reflecting sustained demand and increasing penetration in the Indian pharma market. The company’s efforts to expand its manufacturing capabilities and product pipeline are paying off, as evidenced by its robust performance in the CDMO segment.

As a result, Akums remains committed to strengthening its position as India’s largest CDMO player and expanding its global footprint. The company’s focus on building long-term relationships based on trust and operational excellence will continue to drive its growth in the future.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Akums posts a 10.0% three-month gain, but softens in the last few weeks. Thin margins at 6.5% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 5.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 7.0%, profits at 39.1%, and the PEG sits at 0.98 — below its growth rate. That combination is rare. Check Fundamentals of Akums Drugs and Pharmaceuticals Limited.

Lupin Limited (LUPIN) today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Amifampridine Tablets, 10 mg. This marks a significant milestone as Lupin is now eligible for 180 days of shared generic exclusivity. The tablets are bioequivalent to the reference listed drug (RLD), Firdapse® Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc., for the indication in the approved labeling.

Global Pharmaceutical Leader

Lupin Limited, a global pharmaceutical leader headquartered in Mumbai, India, has a strong presence across the U.S., Other Developed Markets, and Emerging Markets. The company’s diversified portfolio spans generics, complex generics, specialty medicines, and biosimilars. With 15 state-of-the-art manufacturing facilities and 6 research centers, Lupin continues to strengthen its market position through a differentiated portfolio.

Commitment to Innovation

Lupin maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. The company’s dedication to innovation and sustainability is evident through its expansion into diagnostics, digital health, patient-support programs, and disease management initiatives. This latest FDA approval further underscores Lupin’s commitment to enhancing global healthcare access.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lupin Limited

Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Lupin drops 19.7% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The business compounds at 19.1% revenue and 131.5% profit CAGR, with D/E of 0.32. Yet the stock drops 19.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Lupin Limited.